股本结构
单位：万股
| 公告日期 | 2024-03-28 | 2023-11-14 | 2023-11-14 | 2023-08-10 | 2023-07-05 | 2023-05-11 |
|---|---|---|---|---|---|---|
| 证券总股本 | 182.20 | 182.11 | 181.91 | 181.90 | 180.00 | 2687.98 |
| 普通股本 | 182.20 | 182.11 | 181.91 | 181.90 | 180.00 | 2687.98 |
| 优先股 | 2986.37 | 199.09 | 2986.37 | 199.09 | 未披露 | 2986.37 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-12-31 | 2023-11-08 | 2023-09-30 | 2023-08-04 | 2023-07-06 | 2023-05-04 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-28 | 182.20 | 2986.37 |
更多>>
From December 31,2022 to December 31,2023
Issuance of Common Stock pursuant to equity incentive plan
Issuance of Common Stock pursuant to employee stock purchase plan
|
2023-12-31 |
| 2023-11-14 | 182.11 | 199.09 | 定期报告 | 2023-11-08 |
| 2023-11-14 | 181.91 | 2986.37 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock pursuant to equity incentive plan
|
2023-09-30 |
| 2023-08-10 | 181.90 | 199.09 | 定期报告 | 2023-08-04 |
| 2023-07-05 | 180.00 | 未披露 |
更多>>
Talis Biomedical Corporation announced that it will effect a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share, effective at 5:00 p.m. Eastern time on July 5, 2023.
|
2023-07-06 |
| 2023-05-11 | 2687.98 | 2986.37 | 定期报告 | 2023-05-04 |
| 2023-04-28 | 2686.85 | 2986.37 | 定期报告 | 2023-04-17 |
| 2023-05-11 | 2686.76 | 2986.37 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of Common Stock for restricted stock units
Issuance of Common Stock pursuant to employee stock purchase plan
|
2023-03-31 |
| 2023-03-22 | 2686.69 | 2986.37 | 定期报告 | 2023-03-15 |
| 2023-03-22 | 2679.58 | 2986.37 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of Common Stock pursuant to equity incentive plan
Issuance of Common Stock pursuant to employee stock purchase plan
|
2022-12-31 |
| 2022-11-03 | 2678.19 | 2986.37 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of Common Stock pursuant to employee stock purchase plan
Issuance of Common Stock pursuant to vesting of awards under equity incentive plan
|
2022-09-30 |
| 2022-08-02 | 2661.92 | 2986.37 | 定期报告 | 2022-07-27 |
| 2022-05-10 | 2661.89 | 2986.37 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of Common Stock upon exercise of stock options
Issuance of Common Stock pursuant to employee stock purchase plan
|
2022-03-31 |
| 2022-03-15 | 2677.38 | 2986.37 | 定期报告 | 2022-03-10 |
| 2022-03-15 | 2640.80 | 2986.37 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of Common Stock upon exercise of stock options
Issuance of Common Stock pursuant to employee stock purchase plan
Issuance of Common Stock upon initial public offering, net of issuance costs of $21,349
Conversion of convertible preferred stock into common stock and Series 1 convertible preferred stock upon initial public offering
|
2021-12-31 |
| 2021-11-16 | 2628.86 | 2986.37 | 定期报告 | 2021-11-10 |
| 2021-11-16 | 2596.30 | 2986.37 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of Common Stock upon exercise of stock options
Issuance of Common Stock pursuant to employee stock purchase plan
|
2021-09-30 |
| 2021-08-10 | 2569.09 | 2986.37 | 定期报告 | 2021-08-06 |
| 2021-08-10 | 2569.04 | 2986.37 | 定期报告 | 2021-06-30 |
| 2021-05-13 | 2563.76 | 2986.37 |
更多>>
From December 31, 2020 to March 31, 2021
Conversion of convertible preferred stock into common stock and Series 1 convertible preferred stock upon initial public offering
Issuance of Common Stock upon exercise of stock options
Issuance of Common Stock upon initial public offering, net of issuance costs of $21,349
|
2021-03-31 |
| 2021-03-30 | 2563.76 | 2986.37 | 定期报告 | 2021-03-25 |
| 2021-02-12 | 2347.99 | 2986.37 |
更多>>
1.Common stock offered by the company 13,800,000 shares
2.The number of shares of common stock and Series 1 convertible preferred stock to be outstanding after this offering is based on 9,679,876 shares of common stock outstanding as of September 30, 2020
|
2021-02-12 |
From December 31,2022 to December 31,2023
Issuance of Common Stock pursuant to equity incentive plan
Issuance of Common Stock pursuant to employee stock purchase plan
From June 30, 2023 to September 30, 2023
Issuance of common stock pursuant to equity incentive plan
Talis Biomedical Corporation announced that it will effect a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share, effective at 5:00 p.m. Eastern time on July 5, 2023.
From December 31, 2022 to March 31, 2023
Issuance of Common Stock for restricted stock units
Issuance of Common Stock pursuant to employee stock purchase plan
From December 31, 2021 to December 31, 2022
Issuance of Common Stock pursuant to equity incentive plan
Issuance of Common Stock pursuant to employee stock purchase plan
From June 30, 2022 to September 30, 2022
Issuance of Common Stock pursuant to employee stock purchase plan
Issuance of Common Stock pursuant to vesting of awards under equity incentive plan
From December 31, 2021 to March 31, 2022
Issuance of Common Stock upon exercise of stock options
Issuance of Common Stock pursuant to employee stock purchase plan
From December 31, 2020 to December 31, 2021
Issuance of Common Stock upon exercise of stock options
Issuance of Common Stock pursuant to employee stock purchase plan
Issuance of Common Stock upon initial public offering, net of issuance costs of $21,349
Conversion of convertible preferred stock into common stock and Series 1 convertible preferred stock upon initial public offering
From June 30, 2021 to September 30, 2021
Issuance of Common Stock upon exercise of stock options
Issuance of Common Stock pursuant to employee stock purchase plan
From December 31, 2020 to March 31, 2021
Conversion of convertible preferred stock into common stock and Series 1 convertible preferred stock upon initial public offering
Issuance of Common Stock upon exercise of stock options
Issuance of Common Stock upon initial public offering, net of issuance costs of $21,349
1.Common stock offered by the company 13,800,000 shares
2.The number of shares of common stock and Series 1 convertible preferred stock to be outstanding after this offering is based on 9,679,876 shares of common stock outstanding as of September 30, 2020